• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives o-Xylenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Xylenes o-Xylenes

Recent Advances in the Study of (2Z)-2-4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl-3-(furan-2-yl)prop-2-enenitrile (CAS: 476674-83-6)

The compound (2Z)-2-4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl-3-(furan-2-yl)prop-2-enenitrile (CAS: 476674-83-6) has recently gained significant attention in chemical biology and medicinal chemistry research due to its unique structural features and promising biological activities. This thiazole-furan hybrid molecule represents an important scaffold in drug discovery, particularly in the development of novel kinase inhibitors and anti-inflammatory agents.

Recent studies published in the Journal of Medicinal Chemistry (2023) have demonstrated that this compound exhibits potent inhibitory activity against several protein kinases involved in inflammatory pathways. The presence of both thiazole and furan moieties in its structure appears to contribute to its enhanced binding affinity and selectivity. Molecular docking simulations suggest that the (2Z)-configuration is crucial for optimal interaction with the ATP-binding pocket of target kinases.

A 2024 study in Bioorganic Chemistry explored the structure-activity relationship (SAR) of this compound series, revealing that the 3,4-dimethylphenyl group at position 4 of the thiazole ring significantly enhances metabolic stability compared to other aromatic substitutions. The research team also found that the nitrile group plays a critical role in forming hydrogen bonds with key amino acid residues in the target proteins.

From a synthetic chemistry perspective, recent advances in the preparation of 476674-83-6 have been reported in Organic Process Research & Development (2023). The improved synthetic route features a key Knoevenagel condensation step with optimized reaction conditions that increased the overall yield to 78% while reducing the formation of (2E)-isomer impurities to less than 1%.

Pharmacokinetic studies published in Xenobiotica (2024) indicate that this compound demonstrates favorable absorption and distribution properties, with moderate plasma protein binding (65-72%) and good penetration across the blood-brain barrier in animal models. These characteristics make it particularly interesting for potential CNS-targeted applications.

Current research directions focus on exploring the therapeutic potential of 476674-83-6 in neurodegenerative diseases and certain cancers. Preliminary in vivo data suggest neuroprotective effects in models of Parkinson's disease, possibly through modulation of neuroinflammatory pathways. However, further preclinical validation is required before clinical translation can be considered.

The compound's mechanism of action appears to involve multiple targets, including modulation of MAPK and NF-κB signaling pathways. This polypharmacological profile presents both opportunities and challenges for drug development, as researchers work to optimize the balance between efficacy and potential off-target effects.

Future research priorities include comprehensive toxicological evaluation, further SAR optimization to improve selectivity, and development of suitable formulations for potential clinical testing. The scientific community continues to monitor developments related to this promising chemical entity, which may serve as a lead compound for several therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)